Indeed, there was one case of a patient in our cohort with breast cancer and a reversion mutation in BRCA1, with no documented history of having received either a PARP inhibitor or a platinum-based therapy, the two classes of therapy that have been associated with reversion alterations due to their role in capitalizing on the DNA damage repair pathway. The gene discussed is BRCA1; the disease is breast carcinoma.